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Abstract
Background:  Substance P (SP) is a peptide neurotransmitter found in central and peripheral
nerves. SP is involved in the control of smooth muscle, inflammation and nociception. The amino
acid sequence of SP is Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2. Five different forms
of  fluorescently  labeled  SP  have recently been  synthesized,  in  which  Alexa  488,  BODIPY  Fl,
fluorescein, Oregon Green 488 or tetramethylrhodamine has been covalently linked to SP at Lys 3.
Here, these novel analogs are characterized as to their ligand binding, receptor activation and
fluorescence labeling properties.
Results:  Competition binding studies, using radiolabeled [125I] SP, revealed that all of the labeled
forms of SP, except for Alexa 488-SP, effectively competed with radiolabeled SP for binding at the
rat  SP  receptor.  With  the  exception  of  Alexa  488-SP,  all  of  the  SP analogs produced  Ca++
elevations and fluorescence labeling of the SP receptor expressed in Chinese hamster ovary cells.
In SP-responsive neurons, BODIPY Fl-SP and Oregon Green 488-SP were as effective as unlabeled
SP in producing a reduction of the M-type K+ current. Fluorescein-SP produced variable results,
while tetramethylrhodamine-SP was less potent and Alexa 488-SP was less effective on intact
neurons.
Conclusions:  The above results show that fluorescent labeling of SP altered the biological activity
and the binding properties of the parent peptide. Oregon Green 488 and BODIPY FL-SP are the
most useful fluorophores for labeling SP without affecting its biological activity. Given these results,
these probes can now be utilized in further investigations of the mechanisms of SPR function,
including receptor localization, internalization and recycling.
Background
Substance P (SP) is a peptide neurotransmitter that has
been shown to play a role in nociception, smooth muscle
control, allergic responses, inflammation and glandular
secretion [1]. The amino acid sequence of SP was deter-
mined in 1970 [2] after being isolated from mammalian
gastrointestinal tract in 1931 [3]. SP acts as an agonist at
the SP receptor (SPR), known as the neurokinin-1 recep-
tor (NK1) in mammalian systems. SP activation of the
SPR, a G-protein-coupled receptor, has a variety of ef-
fects in the nervous system including inhibition of the M-
type K+ current (IM) [4]. The mechanistic properties of
Published: 13 June 2001
BMC Chemical Biology 2001, 1:1
This article is available from: http://www.biomedcentral.com/1472-6769/1/1
(c) 2001 Bennett and Simmons, licensee BioMed Central Ltd.
Received: 20 May 2001
Accepted: 13 June 2001BMC Chemical Biology (2001) 1:1 http://www.biomedcentral.com/1472-6769/1/1
the SPR have been extensively studied in receptor-ex-
pression systems. When transfected into Chinese ham-
ster ovary (CHO) cells, activation of the SPR results in an
increase in intracellular Ca++ [5], accumulation of inosi-
tol phosphates and cAMP formation [6].
The recent development of intense, photostable and pH-
insensitive fluorophores, along with improvements in
optical detection systems, has led to fluorophore labeling
of many pharmacological agents. Fluorescent probes can
be used to directly label ligand-binding sites without the
use of radioactivity or antibodies. Receptor-labeling with
a fluorophore-conjugated agonist provides advantages
over these conventional methods. The production of an-
tibodies to the receptor protein is not required, as the la-
beled agonist will bind directly to the receptor.
Fluorescence rather than radioactivity can detect the la-
beled ligand, which provides more information on the lo-
calization of the receptor upon SP activation. In addition,
labeled agonists can be used in live cells. Therefore, the
use of fluorescently labeled agents may allow a more ex-
tensive investigation into various receptor functions.
Molecular Probes, Inc. (Eugene, OR) has recently syn-
thesized five fluorophore-conjugated analogs of SP as
potential tools for direct labeling of the SPR. Alexa 488,
BODIPY Fl, fluorescein, Oregon Green 488 and tetrame-
thylrhodamine have been conjugated to the third amino
acid of SP, Lys3. The amine group of Lys provides a con-
venient reactive group for labeling SP without altering its
original amino acid sequence. Alexa 488, BODIPY Fl,
fluorescein and Oregon Green 488 are green fluoro-
phores, while tetramethylrhodamine is a red fluoro-
phore.
We have compared the receptor activation and labeling
of five newly synthesized fluorescent analogs of SP. Each
of the probes has been tested for: 1) ability to bind to the
receptor, 2) receptor activation in both a heterologous
expression system and in native neurons and 3) fluores-
cence labeling of the receptor. This study provides an ex-
tensive characterization of the new SP derivatives that
will provide a basis for future studies involving the fluo-
rescent conjugates. Oregon Green 488 was found to be
the most useful fluorophore for labeling SP without al-
tering its biological activity, whereas Alexa 488 drastical-
ly altered the binding and activation of SP.
Results
Spectra properties of fluorescent analogs
The fluorescent properties of a fluorophore can change
when the fluorophore is attached to another molecule, in
this case a peptide. Furthermore, the conditions under
which fluorescence is measured, such as pH, ionic
strength and buffer composition, can affect fluorescence.
The absorption and emission spectra of the fluorescent
SP analogs were assessed to determine their fluorescence
under experimental conditions used here. As shown in
Fig. 2, the peak excitations of Alexa 488-SP, BODIPY Fl-
SP, fluorescein-SP, Oregon Green 488-SP and tetrame-
thylrhodamine-SP were 490 nm, 505 nm, 495 nm, 495
nm and 560 nm, respectively. The peaks of the emission
curves were 515 nm, 510 nm, 520 nm, 520 nm and 575
nm, respectively.
Epifluorescence microscopy
Direct-labeling of the SPR with fluorescent ligands like
those analyzed in this study would offer advantages over
current methods of receptor labeling. Some of these ad-
vantages include the ability to label live cells and the abil-
ity to conduct receptor labeling without antibodies or
radioactive ligands. Therefore, an important characteris-
tic of the fluorescent SP analogs is their ability to bind to
the SPR and to fluoresce under physiological conditions.
In order to observe the direct-labeling of the SP conju-
gates to the SPR, CHO cells expressing the rat SPR
(rSPR), were incubated with the SP analogs (100 nM) for
2 hrs at 4° C, to prevent internalization of the receptor,
rinsed and fixed. Under these conditions, all of the la-
beled forms of SP, except for Alexa 488-SP, produced
bright membrane staining (Fig. 3). Observation of trans-
fected cells incubated with phosphate buffered saline
(PBS) in the absence of labeled SP conjugate showed that
the transfected cells had some intracellular auto-fluores-
cence (Fig. 3, F). The fluorophore-treated cells also show
some dull intracellular fluorescence, similar to the auto-
fluorescence seen in the unstained control cells. The in-
tensity of the staining produced by the green fluoro-
phores was compared by quantitative analysis. The
intensities of the fluorescence after staining with BOD-
IPY Fl-SP, fluorescein-SP and Oregon Green 488-SP
were significantly greater (p < 0.0001) than the intensity
of the fluorescence of cells treated with Alexa 488-SP.
Tetramethylrhodamine-SP also produced intense mem-
brane staining. The intensity of the staining with tetram-
ethylrhodamine-SP could not be directly compared to
the others due to its different excitation and emission
wavelengths.
The specificity of the fluorescence staining was revealed
by the finding that unlabeled SP effectively prevented the
fluorescent staining of rSPR-transfected CHO cells. The
fluorescence of these cells was similar to that of trans-
fected cells incubated in PBS alone (Fig. 3, F) in that they
possessed some intracellular auto-fluorescence but
lacked membrane staining.
Application of the labeled analogs to untransfected CHO
cells did not produce membrane staining (data not
shown). Only intracellular auto-fluorescence, compara-BMC Chemical Biology (2001) 1:1 http://www.biomedcentral.com/1472-6769/1/1
ble to that observed with transfected cells incubated with
PBS in the absence of labeled SP (Fig. 3, F), was seen in
cells lacking the rSPR.
SP receptor binding
An important determinant of the usefulness of the SP
conjugates is their ability to bind to and activate the SPR.
Therefore, the ability of each of the fluorescent SP ana-
logs to compete with [125I] SP binding to the SPR was as-
sessed using a heterologous expression system, rSPR-
expressing CHO cells. The results are shown in Fig. 4.
The concentration of fluorescent analog required to in-
hibit the binding of radiolabeled SP by 50 % (IC50) was
calculated from the binding studies. The rank order of
potency for the competing peptides was: unlabeled SP
(2.0 nM) > tetramethylrhodamine-SP (4.2 nM) > Ore-
gon Green 488-SP (6.4 nM) > BODIPY-SP (18.0 nM) >
fluorescein-SP (44.5 nM) >>> Alexa 488-SP. Alexa 488-
SP (Fig. 4, A) did not compete with [125I] SP for binding
at the rSPR, therefore an IC50 value could not be deter-
mined.
Two-way analysis of variance followed by Student-New-
man-Keuls test showed that there was a dose-dependent
effect (p < 0.001) on the binding of unlabeled SP and the
SP analogs to the rSPR. Statistical analysis also demon-
strated that the competition binding curves generated by
the SP conjugates were significantly different than the
unlabeled SP binding curve (p < 0.001). Further analysis
showed that, with the exception of the binding curves
produced by tetramethylrhodamine-SP and Oregon
Green 488-SP, a significant difference was seen between
the binding curves of the different SP conjugates (p <
0.05).
Calcium measurements
Activation of the SPR expressed in CHO cells results in
an elevation in intracellular Ca++ [7]. The biological ac-
tivity of the SP conjugates was tested by examining their
Figure 1
Fluorescent SP analog structures. A) Alexa 488-SP, B) BODIPY Fl-SP, C) fluorescein-SP, D) Oregon Green 488-SP and E)
tetramethylrhodamine-SP. The first 5 amino acids of SP (Arg1-Pro2-Lys3-Pro4-Gln5) are shown, with each of the fluorophores
conjugated to Lys3. R = Gln6-Phe7-Phe8-Gly9-Leu10-Met11-NH2. Alexa 488 is the most charged structure, BODIPY Fl is the
smallest, and Alexa 488 and tetramethylrhodamine are the largest.BMC Chemical Biology (2001) 1:1 http://www.biomedcentral.com/1472-6769/1/1
ability to elicit Ca++ elevations. Dose-response curves for
the labeled SP analogs and for unlabeled SP to produce
an increase in intracellular Ca++ in CHO cells transfected
with the rSPR are shown in Fig. 5.
None of the labeled SP analogs produced Ca++ elevations
(n = 3) when added to untransfected CHO cells at a con-
centration of 10 nM (data not shown). When the fluores-
cent derivatives were added at a concentration of 100 nM
they produced an increase in the fluorescence signal due
to the inherent fluorescence of the probes. This could
also be seen in the absence of cells. Due to this interfer-
ence, the activity of the fluorescent probes to produce
Ca++ elevations could not be tested at concentrations
higher than 10 nM.
Alexa 488-SP produced the most prominent increase in
non-specific fluorescence in the absence of cells. When 1
nM or 10 nM Alexa 488-SP was added the fluorophore
produced signals similar in intensity to those observed
when this analog was added to transfected or untrans-
fected CHO cells (data not shown). To determine if Alexa
488-SP could specifically produce a receptor-mediated
Ca++ response, the average of the fluorescence signal
produced by Alexa 488-SP in the absence of cells was
subtracted from the fluorescent signal obtained when Al-
exa 488-SP was added to SPR-expressing CHO cells. The
results showed that Alexa 488-SP did not activate the
SPR to produce a Ca++ response. However, the other four
SP analogs were able to elicit Ca++ responses in rSPR-ex-
pressing CHO cells.
Statistical analysis, two-way analysis of variance fol-
lowed by Student-Newman-Keuls test, demonstrated
that unlabeled SP and the SP analogs, except Alexa 488-
SP, elicited dose-dependent Ca++ elevations (p < 0.001).
Analysis also showed that there was not a significant dif-
ference (p > 0.05) in Ca++ elevations generated by unla-
beled SP or the various SP conjugates, with the exception
of Alexa 488-SP which did not elicit a calcium response.
Figure 2
Spectral analysis. The excitation and emission spectra was determined for (A) Alexa 488-SP, (B) BODIPY Fl-SP, (C) fluores-
cein-SP, (D) Oregon Green 488-SP and (E) tetramethylrhodamine-SP. See results for peak data.BMC Chemical Biology (2001) 1:1 http://www.biomedcentral.com/1472-6769/1/1
Effects of SP analogs on single neurons
The data thus far show that the labeled forms of SP, with
the exception of Alexa 488-SP, can bind to and activate
the receptor in a heterologous expression system. It is
also of importance to determine the activity of the la-
beled ligands in a cell that endogenously expresses the
SPR. The principal neurons of bullfrog sympathetic gan-
glia express a SPR that has been well characterized with
regard to its structure and function. The bullfrog sympa-
thetic ganglia SPR (bfSPR) has 69% homology to the
rSPR at the amino acid level. Perhaps most importantly,
nine of the ten residues that have been demonstrated to
be important for SP binding to mammalian receptors are
conserved in the bullfrog receptor. The effects of SP and
other tachykinins at the bfSPR have been previously well
characterized [8, 9, 5]. The primary biological response
following activation of the ganglionic SPR is inhibition of
the M-type K+ current, IM.
SP produces a dose-dependent inhibition of IM [9]. The
responses of a given neuron to a given form of labeled SP
have been compared to the responses of those same neu-
rons to unlabeled SP at a concentration of 100 nM (Fig.
6). At this concentration SP typically elicits a 70 % de-
pression of IM. BODIPY Fl-SP and Oregon Green 488-SP
produced an inhibition of IM similar to that of unlabeled
SP. Fluorescein-SP was variable in its ability to inhibit
the current, being effective on only two of the four cells
tested. At a concentration of 100 nM, neither Alexa 488-
SP nor tetramethylrhodamine-SP inhibited IM; thus they
were further tested at a concentration of 1 µ M. At this
concentration tetramethylrhodamine-SP inhibited IM by
57 ±  33 %, (n = 4), however Alexa 488-SP did not inhibit
IM. Dose-response curves for the analogs that inhibited
IM and for unlabeled SP are shown in the plots in Fig. 6.
A dose-dependency was observed for the effects of BOD-
IPY Fl-SP, fluorescein-SP and Oregon Green 488-SP.
Discussion
A number of previous studies have demonstrated that
fluorescently labeled ligands are useful probes for study-
ing ligand-receptor interactions [10, 11, 12]. Improved
fluorophores, better optics and the increased sensitivity
of detection systems have led to an increased usage of
fluorescently labeled ligands. It is of vital importance
that additions of fluorescent groups do not alter the nor-
mal functioning of the ligand, for example, by changing
the binding affinity or by altering the receptor activation
Figure 3
Fluorescence microscopy. CHO cells expressing the rSPR were stained with (A) Alexa 488-SP, (B) BODIPY Fl-SP, (C) fluo-
rescein-SP, (D) Oregon Green 488-SP, (E) tetramethylrhodamine-SP and (F) PBS in the absence of a fluorophore. The intensity
to area ratio of Alexa 488-SP was significantly less than the other green fluorophores. However a significant difference was no t
seen between BODIPY Fl-SP, fluorescein-SP or Oregon Green 488-SP.BMC Chemical Biology (2001) 1:1 http://www.biomedcentral.com/1472-6769/1/1
properties of the ligand. If the fluorescent group does al-
ter the properties of the ligand, it is important that these
alterations be understood so that the results obtained
with the labeled ligand can be correctly interpreted. In
this study, we have examined the fundamental conse-
quences of labeling the neuropeptide SP with five differ-
ent fluorescent probes by comparing the effects of the
labeled compounds with those of the parent compound,
SP.
All five of the fluorescent probes were modified at the
Lys3 position with aromatic groups. Alexa 488 and te-
tramethylrhodamine add negative and positive charges,
respectively, to SP. The remaining fluorophores, BOD-
IPY Fl, fluorescein and Oregon Green 488, do not alter
the charge. With regard to size, BODIPY Fl is the small-
est of the fluorophores added, whereas Alexa 488 and te-
tramethylrhodamine are the largest of the fluorophores.
The most significant alteration of the activity of SP was
produced when Alexa 488 was added to SP. The experi-
ments repeatedly showed that Alexa 488-SP does not
posses the same characteristics as unlabeled SP. Alexa
488-SP did not compete with [125I] SP in the competition
binding assay. Consistent with the binding data, this SP
analog did not stain rSPR-transfected CHO cells. Fur-
thermore, Alexa 488-SP did not exhibit functional activ-
ity in two different assays. It failed to elicit a Ca++
response in rSPR-expressing CHO cells and failed to pro-
duce IM inhibition at the bfSPR, both of which are char-
acteristic effects mediated by SP.
Figure 4
Binding of conjugated and unconjugated SP to the rSPR. Competition binding of rSPR transfected CHO cells was per-
formed with 50 pM [125I] SP and increasing concentrations (1 pM, 100 pM, 1 nM, 100 nM and 1 µ M) of each fluorescent SP ana-
l o g.  T h e  c a l c u l at e d  I C 50  values  for  BODIPY  Fl-SP,  fluorescein-SP,  Oregon  Green  488-SP,  tetramethylrhodamine-SP  and
unconjugated SP are 18.0 nM, 44.5 nM, 6.39 nM, 4.20 nM and 1.98 nM, respectively. Note that Alexa 488-SP was unable to dis-
place the radioisotope. Each data point represents an n of at least 4 from 2 or 3 separate experiments.BMC Chemical Biology (2001) 1:1 http://www.biomedcentral.com/1472-6769/1/1
Like Alexa 488, tetramethylrhodamine also adds a
charge to SP, but tetramethylrhodamine-SP generated
an IC50 that was the most similar to that of unlabeled SP.
This SP analog also produced intense staining and typi-
cal Ca++ responses at the rSPR. However, tetramethyl-
rhodamine-SP was ineffective at inhibiting IM at a 100
nM concentration, but did so upon increasing the con-
centration to 1 µ M. Therefore, tetramethylrhodamine-SP
is capable of binding to the SPR and activating Ca++ re-
sponses, but has a decreased potency for inhibiting IM.
Lys3 of SP has been shown to interact with the NH2-ter-
minal extracellular tail (residues 1-21) of the mouse SPR
[13]. Though residues 1-21 of the mouse SPR are prima-
rily conserved in the rSPR, only 5 of the 21 residues are
conserved in the bullfrog SPR. Given the importance of
Lys3 in the mouse SPR, it is therefore conceivable that an
alteration in the charge of the parent compound, SP, as is
the case with Alexa 488-SP and tetramethylrhodamine-
SP, may cause a change in the typical actions of SP. The
addition of Alexa 488 causes a greater change in the
charge of SP, which might inhibit proper ligand-receptor
interaction and thus hinder binding of the SP analog to
the SPR. Tetramethylrhodamine also alters the charge of
SP, but unlike Alexa 488, the fluorophore is positively
charged. Perhaps the addition a single positive charge to
SP by tetramethylrhodamine does not disrupt proper lig-
and/receptor interactions as drastically as the multiple
negative charges that Alexa 488 adds to SP. Therefore,
the less drastic charge alteration made by tetramethyl-
rhodamine may allow the mechanistic characteristics of
Figure 5
Calcium dose response data for the effects of conjugated and unconjugated SP at the rSPR expressed in CHO
cells. Values are the peak Ca++ elevation produced by each drug expressed as the % of the ionomycin response for that cov-
erslip. ANOVA showed significant dose-dependency, but no difference between Ca++ responses produced by the drugs was
shown. Each data point represents the average of at least 5 experiments. Alexa 488-SP is not graphed since it did not elicit spe-
cific Ca++ responses at the rSPR.BMC Chemical Biology (2001) 1:1 http://www.biomedcentral.com/1472-6769/1/1
Figure 6
Top panel - Comparison of the effects of conjugated and unconjugated SP on single neurons. The bars show the
percent inhibition of IM produced by labeled or unlabeled SP at a concentration of 100 nM. Both drugs were applied to the
same cell. Alexa 488-SP and tetramethylrhodamine-SP did not inhibit IM, fluorescein-SP only inhibited the current 50% of the
time, where as BODIPY Fl-SP and Oregon Green 488- SP produced inhibitions similar to unlabeled SP. Bottom panel - IM
inhibition dose response curve for labeled and unlabeled SP. Data is expressed as % IM inhibition. Each point repre-
sents an average of 4 experiments, except fluorescein-SP, which is only an average of 2 experiments. A dose-dependency was
observed for each drug that inhibited the IM.BMC Chemical Biology (2001) 1:1 http://www.biomedcentral.com/1472-6769/1/1
SP to be preserved, albeit with a decreased potency to in-
hibit IM.
Although the structure of fluorescein is very similar to
that of Oregon Green 488 (2', 7'-difluorofluorescein),
fluorescein-SP did not behave in the same manner as Or-
egon Green 488-SP or unlabeled SP. Of the conjugates
that competed with [125I] SP, fluorescein-SP had the low-
est binding affinity as compared to unlabeled SP. The an-
alog was also variable in its ability to inhibit IM at the
bfSPR. However, it consistently produced Ca++ eleva-
tions and membrane staining at the rSPR expressed in
CHO cells.
BODIPY Fl-SP and Oregon Green 488-SP produced inhi-
bition of IM and Ca++ elevations similar to that produced
by unlabeled SP. Thus, labeling with either of these two
fluorophores did not alter the functional activity of SP at
the SPR in either a heterologous expression system or
native cells. These SP analogs also brightly stained the
membranes of rSPR transfected CHO cells. The IC50 val-
ues of BODIPY Fl-SP and Oregon Green 488-SP in com-
petition binding studies were greater than that of
unlabeled SP. When compared to unlabeled SP, Oregon
Green 488-SP and BODIPY FL-SP had a two-fold and
ten-fold increase in binding affinity, respectively. Inter-
estingly, neither BODIPY Fl nor Oregon Green 488 is
charged.
It is interesting to note that although there was a signifi-
cant difference between the binding curves of the fluo-
rescent derivatives of SP and unlabeled SP, there was not
a statistically significant in the peptides' ability to pro-
duce dose-dependent Ca++ elevations. These might be
explained by the differences in the mechanisms that un-
derlie the measurements made in the different experi-
ments. The binding experiments measure the actions of
the peptides at the receptor. Ca++ fluxes indicate addi-
tional mechanisms downstream of the receptor, includ-
ing second messenger activation. The data may reflect
the fact that receptor binding and signal activation are
not strictly correlated in G-protein coupled systems.
The evidence presented here suggests that four of the
analogs, BODIPY Fl-SP, fluorescein-SP, Oregon Green
488-SP and tetramethylrhodamine-SP, are acting specif-
ically at the SPR. Binding analysis showed that the above
conjugates compete with [125I] SP at the rSPR. These
four analogs only produced Ca++ responses in cells
transfected with the SPR; they had no effect in non-
transfected cells. Similarly, membrane staining was ob-
served in transfected CHO cells, but not in untransfected
cells.
Molecular Probes introduced and investigated seven Al-
exa dyes, including Alexa 488, and reported that the dyes
were more fluorescent and more photostable than their
counterparts [14]. In their study, Alexa 488 was com-
pared to fluorescein. The investigators conjugated the
Alexa fluorophores and other similar compounds, such
as fluorescein, to different proteins to compare bright-
ness and stability. They showed that Alexa 488 was
brighter and more stable than fluorescein when conju-
gated to biotin binding proteins, goat anti-mouse IgG
and its F(ab')2 fragments. However, they did not test for
alterations in binding affinities or biological activity after
the addition of the fluorophores.
Another study has examined the effects of fluorescent
conjugation on opioid peptide activity [15]. Alexa 488
and BODIPY TR were used to label dermorphin, del-
trophin, TIPP (Try-Tic-Phe-Phe) and endomorphin by
adding a cysteine to each peptide at the C-terminus, fol-
lowed by conjugation of the fluorophores to the cysteine
residue. The investigators found that the dermorphin
and deltorphin analogs had an increased binding affinity
for the µ - and δ -opioid receptors, respectively, and that
the biological activities of parent compounds were pre-
served. However, when Alexa 488 was conjugated to
TIPP and endomorphin, the binding affinities of the par-
ent compounds were decreased.
Buku et al. [16] synthesized two fluorescent probes for
the vasotocin receptor using fluorescein and tetrameth-
ylrhodamine. These investigators had previously conju-
gated the fluorophores to the seventh position of
vasotocin, a nonapeptide, and found that it had biologi-
cal activity, but that the biological activity was reduced
when compared to the native compound [17]. Therefore,
the investigators conjugated the fluorophores to the
ninth position and found that the analog was 10-fold
more potent than the analog with the fluorophores at the
seventh position. Thus, they concluded that by moving
the bulky fluorophore to the end of vasotocin, and not al-
tering an amino acid involved in binding and activation
of the vasotocin receptor minimized the reduction in bi-
ological activity of the probes.
In summary, our results along with those from other labs
show that, in some cases, conjugation of a specific fluo-
rescent label can be added to a peptide without altering
the activity of the parent compound. In other cases, how-
ever, the activity of the original compound may be dras-
tically altered. Therefore, the biological activity of each
novel fluorophore conjugate must be analyzed. Analysis
of labeled compounds should include assessment of
binding and biological activity as well as brightness and
stability.BMC Chemical Biology (2001) 1:1 http://www.biomedcentral.com/1472-6769/1/1
Conclusions
The results of our study show that there are dramatic dif-
ferences in the function of SP labeled at the Lys3 position
with different fluorophores. Alexa 488, which was the
largest and added the most charged groups to SP, was
unable to label the SPR and altered the biological activity
of SP in live and cultured cells. Oregon Green 488 and
BODIPY Fl, which are smaller and uncharged, appear to
be the most useful fluorophores for labeling SP without
altering the normal functions of SP at the SPR regardless
of the expression system. These results suggest that Ore-
gon Green 488-SP and BODIPY Fl-SP would be the most
useful fluorescent ligands for future studies of the SPR.
Materials and Methods
Labeled peptides
SP labeled with Alexa 488 (S-13426), BODIPY Fl (S-
13425), fluorescein (S-13424), Oregon Green 488 (S-
13427) or tetramethylrhodamine (S-13428) on Lys3 were
purchased from Molecular Probes (Eugene, OR), prod-
uct numbers in parenthesis. The chemical formulae for
the labeled compounds are shown in Fig. 1.
Spectra
Fluorophore spectral analysis was performed on a Perkin
Elmer 512 Spectrofluorometer (Foster City, CA). Alexa
488-SP, BODIPY Fl-SP, fluorescein-SP, Oregon Green
488-SP and tetramethylrhodamine-SP were analyzed at
a concentration of 10 nM, using PBS, pH 7.4, as a solvent.
Epifluorescence microscopy
CHO cells stably transfected with the cDNA of the rSPR
were obtained from Dr. James Krause and maintained as
previously described [18]. Transfected CHO cells were
cultured overnight on 3-well HTC super cured glass
slides (Cel-Line Associates, Inc., Newfield, NJ). The fol-
lowing day, the slides were rinsed with PBS. Two of the
three wells from each slide were stained with 100 nM of
one of the SP conjugates. The third well of each slide
served as a negative control, in that the cells were incu-
bated with PBS in the absence of a SP analog. Slides were
incubated for 2 hrs at 4° C, to prevent internalization of
the receptor and thus provide membrane staining. The
cells were then rinsed and fixed with paraformaldehyde
(2 %) (Fisher Scientific, Pittsburgh, PA) at 4° C for 20
min. Slides were viewed under a Nikon Eclipse E600FN
fluorescent microscope (Fryer Company, Inc., Cincinna-
ti, OH). The green fluorophores were excited using a
FITC (fluorescein isothiocyanate) filter set (excitation
465-495 nm, dichroic 505LP, emission 515-555 nm). The
red fluorophore was excited using a TRITC (tetramethyl-
rhodamine isothiocyanate) filter set (excitation 528-553
nm, dichroic 565LP, emission 600-660 nm). Pictures
were taken with a SPOT camera (Diagnostic Instru-
ments, Inc., Sterling Heights, MI). All digital images of
the green fluorophores were taken at a constant gain (16)
and exposure time (0.7 s) to allow for direct comparison
between cells and experiments. Pictures of tetramethyl-
rhodamine-SP, the red fluorophore, were taken at a gain
of 8 and a 0.4 s exposure time.
The specificity of the fluorescent staining to the rSPR
was analyzed in two ways. First, incubating untransfect-
ed CHO cells with 100 nM of each analog assessed non-
specific staining. Secondly, staining of rSPR-transfected
CHO cells was performed in the presence of an excess of
unlabeled SP. Transfected cells were pretreated with 1
µ M unlabeled SP for 1 hr at 4° C. Then, the cells were
rinsed and incubated with 1 µ M unlabeled SP and 100
nM labeled SP for 1 hr at 4° C. The cells were rinsed, fixed
and viewed as described above.
Image Analysis
Epifluorescence images from the wells containing only
conjugated SP (100 nM) were analyzed using Scion Im-
age (Scion Corporation, Frederick, MD). For each fluor-
ophore, except tetramethylrhodamine, a line was drawn
around the outside of the cell membrane of 10 cells (5
cells/experiment) to create a boundary; the area and pix-
el intensity were then measured within each boundary.
Background, as determined by measuring the intensity
and area of 10 control cells incubated with PBS in the ab-
sence of a fluorophore, was subtracted. Cell area was
used to normalize between cells, thus the ratio of inten-
sity to area was calculated for the treated and untreated
cells.
Receptor binding
Radioligand competition binding assays utilizing CHO
cells stably expressing the rSPR were performed with
Bolton-Hunter [125I] SP (NEN, Boston, MA) at a concen-
tration of 50 pM. Fluorescein-SP, Alexa 488-SP, BOD-
IPY Fl-SP, fluorescein-SP, Oregon Green 488-SP or
tetramethylrhodamine-SP was added at increasing con-
centrations, from 100 pM to 1 µ M, to compete with the
[125I] SP. In order to reach equilibrium, rSPR-expressing
CHO cells (100,000 cells/well) were incubated in a pre-
wetted Millipore Multiscreen 96 well BV filtration plate
(France) with both radiolabeled and fluorescently la-
beled SP at 4° C for 2 hrs. Peptides and cells were pre-
pared in Tris Buffered Saline Binding Buffer: 50 mM
Tris, 120 mM NaCl, 0.2 mg/ml bacitracin, 20 µ g/ml leu-
peptin, 20 µ g/ml chymostatin, 0.1 % bovine serum albu-
min, pH 7.4. Following incubation, cells were filtered
and washed using a Millipore vacuum manifold
(France). Filters were punched and analyzed using a
Packard Cobra II series auto-gamma counter (Meriden,
CT) to determine counts per minute (cpm).BMC Chemical Biology (2001) 1:1 http://www.biomedcentral.com/1472-6769/1/1
Non-specific binding was specified as the counts ob-
tained with 1 µ M unlabeled SP in the presence of radiola-
beled SP. Statistical analysis showed that there was not a
significant difference between the fluorescent conjugates
and unlabeled SP when 1 µ M of SP or its derivatives was
present with 50 pM [125I] SP. In each experiment, specif-
ic binding was determined by subtracting nonspecific
binding from the original cpm measurements. The data
were normalized by calculating B/Bo for each fluoro-
phore, where B is the cpm of [125I] SP specifically bound
in the presence of non-radioactive SP and Bo is the cpm
of [125I] SP specifically bound in the presence of 100 pM
fluorescently labeled SP. The data were plotted as a func-
tion of competitor concentration vs. B/Bo. Sigmoidal
(Hill, 3 parameter) regression was then performed on
the data to determine the IC50, the concentration of flu-
orescent analog required to inhibit the binding of radi-
olabeled SP by 50 %, for each SP analog.
Calcium measurements
Dose-response curves for the ability of the SP analogs to
produce Ca++elevations upon binding to the SPR were
obtained as previously described [5]. Briefly, transfected
CHO cells expressing the rSPR were cultured onto cover-
slips until ∼  90% confluent. The coverslips were incubat-
ed in a Ca++-free solution containing fura-PE3 (AM) and
pluronic acid (Texas Fluorescence Labs, Austin, TX) for
30 min., washed, then incubated in a Ca++-containing
solution for 30 min. A CAF-110 Intracellular Ion Analyz-
er (Jasco Corp., Tokyo, Japan) was used to measure the
fura- PE3 fluorescence emission. Cytosolic Ca++ concen-
trations were measured by taking the ratio of fluores-
cence emission at 510 nm by excitation at 340 and 380
nm. Dose-response curves were obtained by measuring
the Ca++ responses produced by adding various concen-
trations (1 pM, 100 nM, 1 nM and 10 nM) of the labeled
probes. Ionomycin (Sigma, St. Louis, MO) was added at
a concentration of 10 µ M at the end of each experiment
to obtain the maximal Ca++ elevation for that coverslip.
Ca++ responses were measured by subtracting the peak
of each response from the baseline. Responses are ex-
pressed as a fraction of the ionomycin (maximum) re-
sponse.
Two experiments were carried out to serve as negative
controls. In the first control experiment, untransfected
CHO cells were utilized to determine if any of the SP con-
jugates were eliciting Ca++ responses through a pathway
independent of rSPR activation. Each of the SP isoforms
was added to untransfected CHO cells at a concentration
of 10 nM and the signals, if any, were recorded. If a SP
conjugate caused an increase in Ca++ at 10 nM, then 0.1
and 1 nM concentrations for that fluorophore were also
tested.
The second control experiment measured fluorescence
produced by the SP analogs themselves, in the absence of
cells. Each of the SP fluorophores was added to the Ca++
solution in the absence of cells at a concentration of 10
nM and increases in fluorescence, if any, were recorded.
If a response was observed at a 10 nM concentration,
then 0.1 and 1 nM concentrations were also tested for
that SP analog. If a SP analog produced a Ca++ elevation
in either control assay, then the average (n of 3) for the
differences between the baseline and peak Ca++ signals
for that concentration was calculated. The average was
then subtracted from the Ca++ responses observed when
that SP analog was added to transfected and untransfect-
ed CHO cells at that concentration.
Electrophysiology
Single neurons were dissociated from bullfrog sympa-
thetic ganglia as described previously [19]. Briefly, gan-
glia were dissected, treated with enzymes and then
stored in growth medium at 4° C for 1 to 3 days. The gan-
glia were triturated to release single neurons for daily
use.
Whole cell recordings of isolated neurons were conduct-
ed at room temperature, ∼  21° C. Drugs were applied by
single cell superfusion [20] and the bath constantly per-
fused separately with extracellular solution. Whole cell
recordings were made with electrodes with resistances of
0.25-1 MΩ  when filled with intracellular solution.
The compositions of solutions for electrophysiology are
shown in mM unless otherwise noted. Intracellular (or
recording electrode) solution: KCl 120, MgCl2 2, HEPES
10, K4BAPTA 1, ATP 1.15, GTP 0.4, pH 6.8 (with KOH).
Extracellular solution: NaCl 118, KCl 2.4, CaCl2 1.8,
MgCl2 1.8, sodium pyruvate 5, glucose 5, HEPES 10, TTX
0.0003, pH 7.4 (with NaOH). Growth medium: NaCl
118, KCl 2.4, creatine 5.7, glucose 5, sodium pyruvate 5,
100×  MEM vitamins 10 ml/L, penicillin 100 U/ml, strep-
tomycin 100 µ g/ml, 50×  MEM essential amino acids 20
ml/L, 100×  MEM non-essential amino acids 10 ml/L,
HEPES 20, pH 7.4 (with NaOH).
IM was monitored by 500 ms pulses from a holding po-
tential of -30 mV to -50 mV every 8 s. The recordings
were filtered at 1 kHz and stored on magnetic tape. The
IM relaxations were sampled on line at 2.4 kHz. IM was
measured as the amplitude of the current tail following a
voltage step from -50 mV to -30 mV [21]. To quantify the
inhibition of IM, the current before drug and at the max-
imum inhibition during each response were measured
and the percentage of inhibition of IM was calculated.BMC Chemical Biology (2001) 1:1 http://www.biomedcentral.com/1472-6769/1/1
Statistical Analysis
The percent of ionomycin data from the Ca++ elevation
experiments and the B/B0 data from the binding experi-
ments were both subjected to two-way ANOVA analysis,
with the independent variables being fluorescent conju-
gate and dose. One-way ANOVA analysis was used to de-
scribe the intensity to area measurements from the
fluorescent images, except tetramethylrhodamine. These
data, like the data obtained from the binding assay and
Ca++ analysis, were analyzed for variance followed by the
Student-Newman-Keuls test.
Acknowledgements
We thank Drs. Todd Green and Gary Meszaros for many helpful discus-
sions and for generosity in sharing of reagents. This work was supported by 
grant NS25999 from the National Institute of Neurological Diseases and 
Stroke to MAS, by a Summer Undergraduate Research Fellowship from the 
American Society for Pharmacology and Experimental Therapeutics to VJB 
and by a graduate research fellowship from Marshall University and Kent 
State University to VJB.
References
1. Otsuka M, Yoshioka K: Neurotransmitter functions of mamma-
lian tachykinins. Physiol Rev 1993, 73:229-308
2. Chang MM, Leeman SE: Isolation of a sialogogic peptide from
bovine hypothalamic tissue and its characterization as sub-
stance P. J Biol Chem 1970, 245:4784-4790
3. Von Euler US, Gaddum JH:  An unidentified depressor substance
in certain tissue extracts. J Physiol 1931, 72:74-86
4. Adams PR, Brown DA:  Substance P inhibits the M-current in
bullfrog sympathetic neurones. Br J Pharmac 1983, 79:330-333
5. Perrine SA, Whitehead TL, Hicks RP, Szarek JL, Krause JE, Simmons
MA: Solution structures in SDS micelles and functional activ-
ity at the bullfrog substance P receptor of ranatachykinin
peptides. J Med Chem 2000, 43:1741-1753
6. Torrens Y, Beaujouan JC, Saffroy M, Glowinski J, Tence M: Function-
al coupling of the NK1 tachykinin receptor to phospholipase
D in Chinese hamster ovary cells and astrocytoma cells. J
Neurochem 1998, 70:2091-2098
7. Li HS, Leeman SE, Slack BE, Hauser G, Saltsman WS, Krause JE, Blusz-
tajn JK, Boyd ND: A substance P (neurokinin-1) receptor mu-
tant carboxyl-terminally truncated to resemble a naturally
occurring  receptor  isoform  displays  enhanced  responsive-
ness and resistance to desensitization.  PNAS 1997, 94:9475-
9480
8. Akasu T, Ishimatsu M, Yamada K: Tachykinins cause inward cur-
rent  through NK1 receptors in bullfrog  sensory  neurons.
Brain Res 1996, 713:160-167
9. Simmons MA, Brodbeck RM, Karpitskiy VV, Schneider CR, Neff DPA,
Krause JE: Molecular characterization and functional expres-
sion of a substance P receptor from the sympathetic gangli-
on of Rana catesbeiana. Neurosci 1997, 79:1219-1229
10. Heithier H, Hallmann D, Boege F, Reiländer H, Dees C, Jaeggi KA,
Arndt-Jovin D, Jovin TM, Helmreich EJM:  Synthesis and proper-
ties  of  fluorescent  β -adrenoceptor  ligands.  Biochem  1994,
33:9126-9134
11. Tota MR, Daniel S, Sirotina A, Mazina DE, Fong TM, Longmore J,
Strader CD: Characterization of a fluorescent substance P an-
alog. Biochem 1994, 33:13079-13086
12. Turcatti G, Zoffmann S, Lowe J, Drozda S, Chassaing G, Schwartz T,
Chollet  A:  Characterization of non-peptide  antagonist  and
peptide agonist binding sites of the NK1 receptor with fluo-
rescent ligands. J Biol Chem 1997, 272:21167-2117
13. Li YM, Marnerakis M, Stimson ER, Maggio JE: Mapping peptide-
binding domains of the substance P (NK-1) receptor from
P388D1  cells  with  photolabile  agonists.  J  Biol  Chem  1995,
270:1213-1220
14. Panchuk-Voloshina N, Haugland RP, Bishop-Stewart J, Bhalgat MK,
Millard PJ, Mao F, Leung W, Haugland RP: Alexa dyes, a series of
new fluorescent dyes that yield exceptionally bright, photo-
stable conjugates. J Histochem Cytochem 1999, 47:1179-1188
15. Arttamangkul S, Alvarez-Maubecin V, Thomas G, Williams JT, Grandy
DK: Binding and internalization of fluorescent opioid peptide
conjugates in living cells. Mol Pharm 2000, 58:1570-1580
16. Buku A, Masur S, Eggena P: Synthesis and characterization of flu-
orescein- and tetramethylrhodamine-labeled probes for va-
sotocin receptors. Am J Physiol 1989, 257:E804-808
17. Eggena P, Buku A: Synthesis and characterization of a long-act-
ing fluorescent analogue of vasotocin. Biol Cell 1989, 66:1-6
18. Raddatz R, Crankshaw CL, Snider RM, Krause JE: Similar rates of
phosphatidylinositol hydrolysis following activation of wild-
type and truncated rat neurokinin-1 receptors. J Neurochem
1995, 64:1183-1191
19. Simmons MA, Mather RJ: Selectivity of the effects of guanosine-
5'-O-(2-thiodiphosphate) on agonist inhibition of the M cur-
rent  in  amphibian  sympathetic  neurons.  J  Neurosci  1991,
11:2130-2134
20. Simmons MA, Mather RJ: Intracellular guanosine-5'-O-(2-thiodi-
phosphate)  alters  the  dynamics  of  receptor-mediated  re-
sponses  in  bullfrog  sympathetic  neurons.  Mol  Pharm  1992,
41:527-534
21. Simmons MA, Schneider CR,  Krause JE: Regulation of  the  re-
sponses to gonadotropin releasing hormone, muscarine, and
substance P in sympathetic neurons by changes in cellular
constituents  and  intracellular  application  of  peptide  frag-
ments of the substance P receptor.  J Pharm Exp Ther 1994,
271:581-589
Publish with BioMedcentral and every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com